Who is sponsoring NCT03929094?

NCT03929094 is sponsored by Fudan University.

What drugs are being tested in NCT03929094?

Interventions in NCT03929094: Paclitaxel for Injection（Albumin Bound）, Gemcitabine.

What condition does NCT03929094 study?

NCT03929094 studies Metastatic Pancreatic Cancer.

Is NCT03929094 still recruiting?

NCT03929094 is currently status unknown. Last updated 26 April 2019.

Last reviewed 2019-04-26 · How we verify

NCT03929094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Status unknown Phase 2 Last updated 26 April 2019

What this trial tests

Phase 2 trial testing Paclitaxel for Injection（Albumin Bound） in Metastatic Pancreatic Cancer in 120 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 March 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Paclitaxel for Injection（Albumin Bound）
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance.
Xelwa N, Candy GP, Devar J, Omoshoro-Jones J, et al · · 2021 · cited 15× · PMID 34195085 · DOI 10.3389/fonc.2021.683788

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03929094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 26 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing